Literature DB >> 26658575

Comorbidity of atrial fibrillation and heart failure.

Liang-Han Ling1, Peter M Kistler1, Jonathan M Kalman2, Richard J Schilling3, Ross J Hunter3.   

Abstract

Atrial fibrillation (AF) and heart failure (HF) are evolving epidemics, together responsible for substantial human suffering and health-care expenditure. Ageing, improved cardiovascular survival, and epidemiological transition form the basis for their increasing global prevalence. Although we now have a clear picture of how HF promotes AF, gaps remain in our knowledge of how AF exacerbates or even causes HF, and how the development of HF affects the outcome of patients with AF. New data regarding HF with preserved ejection fraction and its unique relationship with AF suggest a possible role for AF in its aetiology, possibly as a trigger for ventricular fibrosis. Deciding on optimal treatment strategies for patients with both AF and HF is increasingly difficult, given that results from trials of pharmacological rhythm control are arguably obsolete in the age of catheter ablation. Restoring sinus rhythm by catheter ablation seems successful in the medium term and improves HF symptoms, functional capacity, and left ventricular function. Long-term studies to examine the effect on rates of stroke and death are ongoing. Guidelines continue to evolve to keep pace with this rapidly changing field.

Entities:  

Mesh:

Year:  2015        PMID: 26658575     DOI: 10.1038/nrcardio.2015.191

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  271 in total

1.  Congestive heart failure in the community: trends in incidence and survival in a 10-year period.

Authors:  M Senni; C M Tribouilloy; R J Rodeheffer; S J Jacobsen; J M Evans; K R Bailey; M M Redfield
Journal:  Arch Intern Med       Date:  1999-01-11

2.  Outcomes with digoxin in atrial fibrillation: more data, no answers.

Authors:  Matthew R Reynolds
Journal:  J Am Coll Cardiol       Date:  2014-08-19       Impact factor: 24.094

3.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

Review 4.  Management of atrial fibrillation in the setting of heart failure.

Authors:  H J Crijns; M P Van den Berg; I C Van Gelder; D J Van Veldhuisen
Journal:  Eur Heart J       Date:  1997-05       Impact factor: 29.983

5.  Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure.

Authors:  K Komamura; R P Shannon; A Pasipoularides; T Ihara; A S Lader; T A Patrick; S P Bishop; S F Vatner
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

6.  Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure.

Authors:  G W Moe; T P Stopps; R J Howard; P W Armstrong
Journal:  J Lab Clin Med       Date:  1988-10

7.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

8.  The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog.

Authors:  A J Riegger; G Liebau
Journal:  Clin Sci (Lond)       Date:  1982-05       Impact factor: 6.124

9.  Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.

Authors:  Shi-Jun Li; Ulrik Sartipy; Lars H Lund; Ulf Dahlström; Martin Adiels; Max Petzold; Michael Fu
Journal:  Circ Heart Fail       Date:  2015-08-04       Impact factor: 8.790

10.  Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction.

Authors:  Masao Sakabe; Akira Fujiki; Kunihiro Nishida; Masataka Sugao; Hidehiko Nagasawa; Takayuki Tsuneda; Koichi Mizumaki; Hiroshi Inoue
Journal:  J Cardiovasc Pharmacol       Date:  2004-06       Impact factor: 3.105

View more
  50 in total

1.  Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.

Authors:  A Mantovani; R Rigolon; A Civettini; B Bolzan; G Morani; S Bonapace; C Dugo; G Zoppini; E Bonora; G Targher
Journal:  J Endocrinol Invest       Date:  2017-07-15       Impact factor: 4.256

2.  Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

Authors:  David F Briceño; Timothy M Markman; Florentino Lupercio; Jorge Romero; Jackson J Liang; Pedro A Villablanca; Edo Y Birati; Fermin C Garcia; Luigi Di Biase; Andrea Natale; Francis E Marchlinski; Pasquale Santangeli
Journal:  J Interv Card Electrophysiol       Date:  2018-07-31       Impact factor: 1.900

Review 3.  Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.

Authors:  Aakash Bavishi; Ravi B Patel
Journal:  Heart Fail Clin       Date:  2020-07-21       Impact factor: 3.179

4.  Interleukin-37 elevation in patients with atrial fibrillation.

Authors:  Weidong Li; Shijie Li; Xianjin Li; Shuzhong Jiang; Bing Han
Journal:  Clin Cardiol       Date:  2016-11-02       Impact factor: 2.882

5.  Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care.

Authors:  Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  J Hypertens       Date:  2018-09       Impact factor: 4.844

6.  The association between relevant co-morbidities and prevalent as well as incident heart failure in patients with atrial fibrillation.

Authors:  Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  J Cardiol       Date:  2018-02-01       Impact factor: 3.159

Review 7.  Anticoagulation in atrial fibrillation with heart failure.

Authors:  Lei Zhao; William Y S Wang; Xinchun Yang
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

8.  High molecular weight fibroblast growth factor-2 as a promising prognostic biomarker to predict the occurrence of heart failure in atrial fibrillation patients.

Authors:  Ling-Yue Sun; Xiang Qu; Ling-Zhi Chen; Xing-Xing Chen; Gao-Shu Zheng; Zhi-Ting Wang; Wei-Jian Huang; Hao Zhou
Journal:  Heart Vessels       Date:  2017-07-08       Impact factor: 2.037

9.  Catheter Ablation for Rate-Controlled Atrial Fibrillation: New Horizon in Heart Failure Treatment.

Authors:  Oussama M Wazni; Mina K Chung
Journal:  J Am Coll Cardiol       Date:  2017-08-27       Impact factor: 24.094

Review 10.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.